Eli Lilly 2007 Annual Report Download - page 11

9
CORPORATE RESPONSIBILITY
Throughout our history, Lilly has been a leading corporate
citizen. While our greatest contributions to society are
breakthrough medicines for patients around the world,
we realize that positive patient outcomes are about more
than just medicine.
At Lilly, our corporate responsibility is focused on
making a measurable difference in business and soci-
ety. We are committed to operating our business at the
highest standards, including being an industry leader in
transparency, using our resources to strengthen the com-
munities in which we live and work, and looking beyond
our operations to help address health challenges.
While we regard this as a journey, we are proud of
our record as a global corporate citizen. Here are some
examples:
Commitment to Transparency
We continue to be an industry leader in transparency.
In 2004, we were the fi rst pharmaceutical company to
publish online the results of all our clinical trials. We have
an unwavering commitment to publicly disclosing medi-
cal research results—whether favorable or unfavorable
for Lilly—in an accurate, objective, and balanced manner
to ensure our customers have the information they need
about our products.
In addition, in 2007 Lilly became the fi rst pharmaceu-
tical company to disclose publicly all of our grants to U.S.
nongovernmental organizations, research institutions,
and others. This information is available online at www.
lillygrantoffi ce.com.
Philanthropy and Community Support
Lilly also continues to build on its long tradition
of philanthropy and community support. According to
the Chronicle of Philanthropy, the company’s 2006 giv-
ing placed it sixth among the 91 major U.S. companies
responding to its survey. In 2007, our philanthropic
contributions totaled about $315 million, including about
$240 million in products for patient assistance programs
and international humanitarian causes. Our total 2007
giving represents about 6 percent of our adjusted income
before taxes and has positioned Lilly once again as one of
the most charitable companies in the world.
We also launched a new employee volunteer initia-
tive called “Hands and Hearts,” which aims to enhance
employee involvement with nonprofi t organizations while
allowing us to track and measure results. By encouraging
volunteerism, we strengthen our communities and in-
crease the commitment and engagement of our workforce.
Improving Access to Medicines
Access to health care—and to affordable medicines—
is a major problem in many countries, and Lilly has taken
steps to assist. For example, in 2007, we helped more than
145,000 patients in the U.S. obtain medicines through six
different assistance programs. These programs are part of
a broader industry effort. Through the Partnership for Pre-
scription Assistance program (PPARx), the pharmaceutical
industry has helped more than 4 million people get afford-
able access to needed medicines. Additional information
on PPARx may be found at www.pparx.org.
Fighting Multidrug-Resistant Tuberculosis (MDR-TB)
MDR-TB is a growing global health threat. Begun in
2003, Lilly’s groundbreaking MDR-TB Partnership seeks to
increase the supply and availability of two important medi-
cines to treat the deadly disease in the hardest-hit countries.
In March 2007, we increased our fi nancial commitment
by an additional $50 million. And in June, we announced
the creation of an ambitious public–private consortium in
Seattle to conduct early-phase discovery research of new
medicines urgently needed to treat tuberculosis, including
emerging resistant strains, with another $15 million invest-
ment—bringing our total contributions to $135 million. In
2007, our efforts were recognized by the Global Business
Coalition, which described our MDR-TB program as a “su-
perlative model” for other businesses to follow.
Supporting Novel Approaches in the Battle Against
Diabetes
In keeping with Lilly’s strong and historic commit-
ment to diabetes, the Lilly Foundation is contributing up
to $15 million to the American Academy of Family Physi-
cians Foundation to establish “Peers for Progress,” a pro-
gram that will identify and train lay volunteers who have
diabetes and empower them to be “diabetes mentors.”
These mentors will then assist other people with diabetes
to better manage the emotional, social, and daily self-
care demands of the disease. The goal of this ambitious
initiative is to empower 200,000 volunteers, or 1 percent
of Americans with diabetes, to become diabetes mentors
and to expand this program globally. In addition, Lilly is
providing an educational grant of $10 million to the Inter-
national Diabetes Federation to fund “Project BRIDGES,” a
global effort to identify and share successful strategies for
managing diabetes.
For a full report on Lilly’s corporate citizenship initiatives,
please visit www.lilly.com/about/citizenship.
Beyond Medicine: Providing Answers That Matter